Medicare Fraud 101
Guess What Else is NOT a Top Priority of the FDA?
Answer: Monitoring postmarketing study commitments.
The FDA lacks an effective system for monitoring postmarketing study commitments. See the latest OIG Report, dated June 2006.
No Tags| Posted By Marcella Auerbach | |
| Category Medicare Fraud | Posted July 12th, 2006 |
| Bookmark | |
Leave a Reply
Regulatory Documents (PDFs)
- OIG Compliance Program Guidance for Hospitals
- OIG Supplemental Compliance Program Guidance for Hospitals
- OIG Compliance Program Guidance for the Durable Medical Equipment, Prosthetics, Orthotics & Supply Industry
- OIG Compliance Program Guidance for Hospices
- OIG Compliance Program Guidance for Clinical Laboratories
- OIG Compliance Program Guidance for Home Health Agencies
- OIG Final Compliance Program Guidance for Nursing Facilities
- OIG Final Compliance Program Guidance for Medicare+Choice Organizations
- OIG Compliance Program Guidance for Third Party medical Billing Companies
- OIG Pharma Compliance Program Guidance for Ambulance Suppliers
- OIG Guidance on Voluntary Disclosure of Healthcare Fraud
- HHS-OIG 2002 Work Plan
- HHS-OIG 2003 Work Plan
- HHS-OIG 2004 Work Plan
- HHS-OIG 2005 Work Plan
- HHS-OIG 2006 Work Plan
Nolan Law Firm Articles
Medicare Links
- Pages
- Categories
- Medicare Fraud (45)
- Feeds
- Archives
Nolan & Auerbach, P.A. is a qui tam law firm whose practice is uniquely limited to healthcare fraud cases under the qui tam provisions of the False Claims Act. We know healthcare fraud because that's what we do! Toll free: 800-FRAUD 04
"The hiring of a lawyer is an important decision that should not be based
solely on advertisements. Before you decide, ask us to send you free written
information about our qualifications and experience."
Licensed in Florida
Located in Fort Lauderdale, Florida
Available for National Cases